ProCE Banner Activity

CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

Slideset Download
Conference Coverage
Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.

Released: June 03, 2020

Expiration: June 02, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono